Background: New onset of diabetes after transplantation (NODAT) is an important problem as it increases infectious and cardiovascular complications reducing patient and graft survival.

Aim: To establish the impact of perioperative hyperglycemia on the development of NODAT and the other known risk factors for its development in patients who go to renal transplant surgery, in a renal transplant unit dependent on an academic center.

Methods: Study of cases and controls of patients with renal transplantation who developed or not NODAT within the year of follow-up, with more than 18 years of age, with the same immunosuppressive scheme (prednisone, tacrolimus, mycophenolate mofetil).

Results: Of 71 transplanted patients, 14 (19.7%) developed NODAT per year, with an average age of 37.57 ± 15.02 years vs. 36.08 ± 12.43 years for those who did not develop it (p: 0, 73) respectively; those who developed NODAT were male in 57.14% vs. 70.18% of those who did not develop it respectively. Patients whose preoperative laboratory evaluation showed blood glucose equal to or greater than 100 mg/dl and less than 126 mg/dl had a NODAT frequency of 21.3% vs. 5.26% (OR 4.9 p: 0.005) in those who they had values ​​lower than 100 mg/dl at the same time of the evaluation. In addition, if the blood glucose prior to hospital discharge was ≥140 mg/dl, the frequency of NODAT was 35.71% vs. 1.75% (OR 31.11 p: 0.0003) if the blood glucose was lower than 140 mg/dl at the same time of the evaluation. None of the other risk factors considered: age >40 years, female sex, overweight, obesity, hypertriglyceridemia, family history of diabetes had significant statistical differences between the two groups.

Conclusion: In our experience, poor glycemic controls, especially before surgery and prior to hospital discharge, marked a higher frequency trend of NODAT one year after follow-up. The patients presenting with this phenomenon should be observed with special attention in the follow up.

Disclosure

M. Méndez Ferreira: None. E.D. Bueno: None. A. Benitez: None. C.M. Palacios: None. J.T. Jimenez: None. A. Amarilla: None. F. Da Ponte: None. I. Stanley: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.